228.55
Real-Time Quote
 +1.88 / +0.83%
Today’s Change
143.71
Today|||52-Week Range
249.94
+36.04%
Year-to-Date
Report: Actavis, Sanofi To Bid On Over-The-Counter Drug Maker
Oct 20 / Benzinga
Impax Laboratories Inc. (IPXL) in Focus: Stock Rises 11.8% - Tale of the Tape
Oct 10 / Zacks.com
Benzinga's M&A Chatter for Monday October 20, 2014
Oct 20 / Benzinga
Teva Starts Rolling Submission of its Pain Drug CEP-33237 - Analyst Blog
Oct 09 / Zacks.com
Valeant hints at higher bid for Allergan
Oct 20 / FT.com
Ligand Provides Better-than-Expected Q3 Earnings Guidance - Analyst Blog
Oct 09 / Zacks.com
Pfizer's AstraZeneca pursuit knocked by Shire deal collapse
Oct 17 / FT.com
Actavis plc and Valeant Pharmaceuticals Inc. Battle for Allergan Inc.: Who Wins?
Oct 09 / MotleyFool.com
Ironwood/Actavis Move Linzess into Phase II Study for OIC - Analyst Blog
Oct 17 / Zacks.com
Takeover target Allergan raises guidance
Oct 09 / FT.com
Aquinox Pharmaceuticals (AQXP) Jumps: Stock Soars 22.4% - Tale of the Tape
Oct 17 / Zacks.com
Allergan: Three's Company
Oct 08 / FT.com
Some inversion deals may survive tax changes
Oct 16 / FT.com
Valeant and Pershing look to sweeten Allergan bid by $4.5bn
Oct 07 / FT.com
Actavis Confirms Generic Quillivant XRB. Patent Challenge
Oct 16 / Benzinga
Teva to Concentrate on Core Specialty Therapeutics - Analyst Blog
Oct 07 / Zacks.com
Supernus' Trokendi XR Faces Generic Threat from Zydus - Analyst Blog
Oct 15 / Zacks.com
Actavis in Acquisition Mode, Durata Deal to Boost Portfolio - Analyst Blog
Oct 07 / Zacks.com
Mallinckrodt Gives FY15 Guidance Post Questcor Acquisition - Analyst Blog
Oct 15 / Zacks.com
Eli Lilly Stops Developing Tabalumab Due to Efficacy Issues - Analyst Blog
Oct 07 / Zacks.com
Pacira (PCRX) Reveals Additional Safety Data on Exparel - Analyst Blog
Oct 14 / Zacks.com
AbbVie's Humira Label Expanded in U.S. - Analyst Blog
Oct 07 / Zacks.com
3 Best Performing Mutual Funds of 2014 - Mutual Fund Commentary
Oct 13 / Zacks.com
Progenics Gets $40M Milestone on FDA Approval of Relistor - Analyst Blog
Oct 07 / Zacks.com
AxoGen (AXGN) Shows Strength: Stock Up 15.4% in Session - Tale of the Tape
Oct 13 / Zacks.com
Horizon Pharma's Actimmune Gets Orphan Drug Designation - Analyst Blog
Oct 07 / Zacks.com
Zacks Rank #1 Additions for Monday - Tale of the Tape
Oct 13 / Zacks.com
Stock Market News for October 07, 2014 - Market News
Oct 07 / Zacks.com
Endo to Buy Auxilium for $2.6B, Diversify Portfolio - Analyst Blog
Oct 10 / Zacks.com
Zacks Rank #1 Additions for Tuesday - Tale of the Tape
Oct 07 / Zacks.com
Allergan Raises Outlook amidst Valeant Takeover Attempts - Analyst Blog
Oct 10 / Zacks.com
Salix pulls deal amid US tax crackdown
Oct 03 / FT.com
Impax Up, Set to Buy Tower Holdings & Lineage Therapeutics - Analyst Blog
Oct 10 / Zacks.com
Shrewd investor Carl Icahn is killing it
Sep 30 / CNNMoney.com

To view my watchlist

Not a member yet?

Sign up now for a free account
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.